- Home
- LFCR vs PCF Comparison
LFCR vs PCF Comparison
Compare LFCR & PCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFCR
- PCF
- Stock Information
- Founded
- LFCR 1986
- PCF 1987
- Country
- LFCR United States
- PCF United States
- Employees
- LFCR N/A
- PCF N/A
- Industry
- LFCR Biotechnology: Pharmaceutical Preparations
- PCF Trusts Except Educational Religious and Charitable
- Sector
- LFCR Health Care
- PCF Finance
- Exchange
- LFCR Nasdaq
- PCF Nasdaq
- Market Cap
- LFCR 224.6M
- PCF 196.9M
- IPO Year
- LFCR N/A
- PCF N/A
- Fundamental
- Price
- LFCR $6.36
- PCF $6.66
- Analyst Decision
- LFCR Buy
- PCF
- Analyst Count
- LFCR 3
- PCF 0
- Target Price
- LFCR $8.00
- PCF N/A
- AVG Volume (30 Days)
- LFCR 127.8K
- PCF 74.8K
- Earning Date
- LFCR 01-02-2025
- PCF 01-01-0001
- Dividend Yield
- LFCR N/A
- PCF 10.90%
- EPS Growth
- LFCR N/A
- PCF N/A
- EPS
- LFCR N/A
- PCF N/A
- Revenue
- LFCR $130,858,000.00
- PCF N/A
- Revenue This Year
- LFCR $2.24
- PCF N/A
- Revenue Next Year
- LFCR $7.88
- PCF N/A
- P/E Ratio
- LFCR N/A
- PCF N/A
- Revenue Growth
- LFCR 16.47
- PCF N/A
- 52 Week Low
- LFCR $3.68
- PCF $5.71
- 52 Week High
- LFCR $7.99
- PCF $6.96
- Technical
- Relative Strength Index (RSI)
- LFCR 58.66
- PCF 41.13
- Support Level
- LFCR $6.00
- PCF $6.60
- Resistance Level
- LFCR $5.96
- PCF $6.88
- Average True Range (ATR)
- LFCR 0.29
- PCF 0.07
- MACD
- LFCR 0.09
- PCF -0.02
- Stochastic Oscillator
- LFCR 81.51
- PCF 18.97
About LFCR Lifecore Biomedical Inc.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that offers differentiated capabilities in the development, filling, and finishing of complex sterile injectable pharmaceutical products in syringes and vials. It manufactures injectable-grade Hyaluronic Acid. Lifecore recognizes revenue in two different product categories, CDMO and fermentation.
About PCF High Income Securities Fund
High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective primarily by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.